CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from November 15-19, 2024 in San Diego. Bill Sibold, Chief Executive Officer of Madriga ...

Madrigal Pharmaceuticals (NASDAQ: MDGL ) has been on my radar for some time due to its lead candidate Rezdiffra. However, I've held off from initiating a position up until now, primarily due to concerns about the company's overvaluation. It felt as if He is the leader of the investing group Compounding Healthcare . Features of the group include: Several model healthcare portfolios, a weekly newsletter, a daily watchlist, and chat for dialogue and questions. Learn more Biologics is a full-time healthcare inv ...

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomesStudy may also support full approval of RezdiffraTM (resmetirom) in noncirrhotic NASH CONSHOHOCKEN, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis ...

CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. Following the announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals webs ...

CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024. The fireside chat will be webcast live and may be accessed here or by visiting Madrigal's website's Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madrigal Pharmaceut ...

It has been about a month since the last earnings report for Madrigal (MDGL) . Shares have added about 1% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Madrigal due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Madrigal Q2 Earnings Top, NASH Drug Drives Top Lin ...

Global Research and Evidence Lab 14 August 2024 Madrigal Pharmaceuticals Inc Rezdiffra Formulary Coverage Tracker Rezdiffra coverage substantially improves in July update (50% commercial coverage, consistent w/mgmt commentary). See inside for an overview of the data on coverage and formulary status plan by plan and how Rezdiffra coverage is changing over time. We update our proprietary monthly formulary coverage tracker for MDGL's Rezdiffra using Evidence Lab's US drug formulary monitor (access data here). ...

One player's minor pain is another's moderate gain. It's not often that a biotech wins when a big pharma stumbles, but Madrigal Pharmaceuticals (MDGL 0.64%) is now in a better place than before because of a setback at Danish drug giant Novo Nordisk (NVO 2.83%). The two cardiometabolic drug developers will avoid direct competition for the time being, and now, any head-tohead match up in the future could favor Madrigal a bit more than before. But is the biotech still a buy? Let's clarify the question by looki ...

11 1 15 F H H t I P T Ti I i 1 I T n H Klaus Vedfelt Introduction Madrigal Pharmaceutical's (NASDAQ:MDGL) stock is essentially unchanged since my last look in June, when I expressed concern over GLP-1s, like Eli Lilly's (LLY) Zepbound, popping up in treatment guidelines for metabolic dysfunction-associated steatohepatitis (MASH), effectively limiting the market for Rezdiffra, the first drug indicated for MASH. Rezdiffra reported Q2 '24 earnings on Wednesday, the company's first quarter since its launch (via ...

Madrigal Pharmaceuticals (MDGL) reported a loss of $7.10 per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of $7.55. In the year-ago quarter, the company reported a loss of $4.69. During the quarter, the company generated total revenues of $14.6 million — entirely from product sales of its recently approved nonalcoholic steatohepatitis (NASH) drug Rezdiffra, which was commercially launched this April. The metric beat the Zacks Consensus Estimate of $3.8 million. Since th ...